The Lancet regional health. Southeast Asia最新文献

英文中文

The Lancet Regional Health—Southeast Asia: 2025 year in review 《柳叶刀-区域卫生-东南亚：2025年回顾》

IF 6.2 Q1 HEALTH CARE SCIENCES & SERVICES

The Lancet regional health. Southeast Asia

Pub Date : 2025-12-01 Epub Date: 2025-12-19 DOI: 10.1016/j.lansea.2025.100704

Shalini Garg, Bhavani Nivetha, Apoorva Dharmendra

引用次数: 0

Indonesia leaves SEARO: what it means for regional health and WHO 印度尼西亚离开SEARO：它对区域卫生和世卫组织意味着什么

IF 6.2 Q1 HEALTH CARE SCIENCES & SERVICES

The Lancet regional health. Southeast Asia

Pub Date : 2025-12-01 Epub Date: 2025-08-27 DOI: 10.1016/j.lansea.2025.100660

Habib Benzian , Manu Raj Mathur

引用次数: 0

Tiny lives, big failures: India's drug regulation crisis 微小的生命，巨大的失败：印度的药品监管危机

IF 6.2 Q1 HEALTH CARE SCIENCES & SERVICES

The Lancet regional health. Southeast Asia

Pub Date : 2025-12-01 Epub Date: 2025-12-19 DOI: 10.1016/j.lansea.2025.100705

The Lancet Regional Health – Southeast Asia

引用次数: 0

Nafithromycin in CABP: promise and precaution—authors’ reply 纳非霉素在CABP中的应用前景与预防措施——作者的回复

IF 6.2 Q1 HEALTH CARE SCIENCES & SERVICES

The Lancet regional health. Southeast Asia

Pub Date : 2025-12-01 Epub Date: 2025-11-13 DOI: 10.1016/j.lansea.2025.100696

Himanshu Pophale , Monica Gupta , Hariharan Periasamy , Balaji Veeraraghavan , Sachin Bhagwat

引用次数: 0

Delandistrogene Moxeparvovec gene therapy for Duchenne muscular dystrophy: the way forward in South Asian countries 杜氏肌营养不良症的Delandistrogene moxparvovec基因治疗：南亚国家的前进之路

IF 6.2 Q1 HEALTH CARE SCIENCES & SERVICES

The Lancet regional health. Southeast Asia

Pub Date : 2025-12-01 Epub Date: 2025-11-28 DOI: 10.1016/j.lansea.2025.100699

Priyanka Madaan , Santosh Kumar Mishra , Jithangi Wanigasinghe , Jitendra Kumar Sahu

引用次数: 0

Concerns on construct validity and contamination in the Lay-CARE study Lay-CARE研究中对结构效度和污染的关注

IF 6.2 Q1 HEALTH CARE SCIENCES & SERVICES

The Lancet regional health. Southeast Asia

Pub Date : 2025-12-01 Epub Date: 2025-08-12 DOI: 10.1016/j.lansea.2025.100652

Yilin Jiang , Narina A. Samah , Heng Zhou

引用次数: 0

Beyond immunogenicity in XBB.1.5 subunit COVID-19 boosters focusing on durability, dosing, and target populations: authors reply 超越XBB.1.5亚单位COVID-19增强剂的免疫原性，重点是持久性，剂量和目标人群：作者回复

IF 6.2 Q1 HEALTH CARE SCIENCES & SERVICES

The Lancet regional health. Southeast Asia

Pub Date : 2025-12-01 Epub Date: 2025-10-03 DOI: 10.1016/j.lansea.2025.100678

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Rammohan Reddy Mogulla, Vijay Yerroju, Siddalingaiah Ningaiah, Mallikarjuna Panchakshari, Chirag Dhar

引用次数: 0

Pregnancy and neonatal outcomes of term deliveries of singleton pregnancies at different gestations in Sri Lanka: a multicentre prospective study 斯里兰卡不同妊娠期单胎妊娠足月分娩的妊娠和新生儿结局：一项多中心前瞻性研究

IF 6.2 Q1 HEALTH CARE SCIENCES & SERVICES

The Lancet regional health. Southeast Asia

Pub Date : 2025-11-01 Epub Date: 2025-10-03 DOI: 10.1016/j.lansea.2025.100677

Sachith Mettananda , Himali Herath , Ranod Madushith , Tiran Dias , Rasika Herath , Sampatha Goonewardena , Dhammica Rowel , Abner Elkan Daniel , Susie Perera

Background

Delivery at ‘term’ is considered low risk for mothers and neonates. Evidence suggests variable outcomes at different gestations, even within ‘term’. This study aims to compare pregnancy characteristics and neonatal outcomes of delivery at different gestations at ‘term’.

Methods

We analysed the data of the island-wide multicentre Sri Lanka Birth Weight Study, which recruited all live-born newborns in 13 hospitals over 2 months in 2023. Only data of singleton pregnancies and term neonates were included. Pregnancy complications and neonatal outcomes of each gestation were analysed by logistic regression.

Findings

8053 ‘term’ singleton deliveries (1805, 2367, 2087, 1762, and 32 at 37, 38, 39, 40 and 41 weeks) were included. A higher proportion of mothers delivering at 37 weeks had pregestational diabetes (AOR: 7.84, 95% CI: 4.24–14.37), chronic hypertension (AOR: 4.37, 95% CI: 2.01–9.49), pregnancy-induced hypertension (AOR: 2.65, 95% CI: 1.92–3.66) and gestational diabetes (AOR: 1.96, 95% CI: 1.57–2.44) compared to mothers delivering at 39 weeks. The elective caesarean section rate was highest at 37 weeks (783, 43.4%) compared to 38 weeks (737, 31.1%) or higher gestations. Delivery at 37 weeks was associated with inferior neonatal outcomes of 5-min APGAR <8 (AOR: 3.04, 95% CI: 1.36–6.76), requiring resuscitation (AOR: 1.74, 95% CI: 1.27–2.38) and admission to intensive care (AOR: 1.62, 95% CI: 1.09–2.41) compared to 38 weeks.

Interpretation

Neonates born at 38 weeks showed better outcomes than those born at 37 weeks. When elective delivery is necessary, postponing it from 37 weeks to at least 38 weeks would positively impact neonatal outcomes.

Funding

UNICEF, Sri Lanka, funded the Sri Lanka Birth Weight Study. No funding obtained for this manuscript.

足月分娩被认为对母亲和新生儿的风险较低。有证据表明，即使在“足月”内，不同妊娠的结果也是不同的。本研究旨在比较不同妊娠期“足月”分娩的妊娠特征和新生儿结局。方法分析斯里兰卡全岛多中心出生体重研究的数据，该研究招募了2023年13家医院2个月以上的所有活产新生儿。仅包括单胎妊娠和足月新生儿的数据。采用logistic回归分析各妊娠期的妊娠并发症及新生儿结局。研究结果包括8053例“足月”单胎分娩（1805、2367、2087、1762和32例在37、38、39、40和41周）。与39周分娩的母亲相比，37周分娩的母亲患有妊娠期糖尿病（AOR: 7.84, 95% CI: 4.24-14.37）、慢性高血压（AOR: 4.37, 95% CI: 2.01-9.49）、妊娠性高血压（AOR: 2.65, 95% CI: 1.92-3.66）和妊娠期糖尿病（AOR: 1.96, 95% CI: 1.57-2.44）的比例更高。选择性剖宫产率在妊娠37周（783例，43.4%）高于妊娠38周（737例，31.1%）或更高时最高。与38周相比，37周分娩与5分钟APGAR <；8 （AOR: 3.04, 95% CI: 1.36-6.76）、需要复苏（AOR: 1.74, 95% CI: 1.27-2.38）和入院重症监护（AOR: 1.62, 95% CI: 1.09-2.41）的新生儿预后较差相关。38周出生的新生儿比37周出生的新生儿表现出更好的结局。当需要择期分娩时，将其从37周推迟到至少38周将对新生儿结局产生积极影响。斯里兰卡联合国儿童基金会资助了斯里兰卡出生体重研究。本文未获资助。

{"title":"Pregnancy and neonatal outcomes of term deliveries of singleton pregnancies at different gestations in Sri Lanka: a multicentre prospective study","authors":"Sachith Mettananda , Himali Herath , Ranod Madushith , Tiran Dias , Rasika Herath , Sampatha Goonewardena , Dhammica Rowel , Abner Elkan Daniel , Susie Perera","doi":"10.1016/j.lansea.2025.100677","DOIUrl":"10.1016/j.lansea.2025.100677","url":null,"abstract":"<div><h3>Background</h3><div>Delivery at ‘term’ is considered low risk for mothers and neonates. Evidence suggests variable outcomes at different gestations, even within ‘term’. This study aims to compare pregnancy characteristics and neonatal outcomes of delivery at different gestations at ‘term’.</div></div><div><h3>Methods</h3><div>We analysed the data of the island-wide multicentre Sri Lanka Birth Weight Study, which recruited all live-born newborns in 13 hospitals over 2 months in 2023. Only data of singleton pregnancies and term neonates were included. Pregnancy complications and neonatal outcomes of each gestation were analysed by logistic regression.</div></div><div><h3>Findings</h3><div>8053 ‘term’ singleton deliveries (1805, 2367, 2087, 1762, and 32 at 37, 38, 39, 40 and 41 weeks) were included. A higher proportion of mothers delivering at 37 weeks had pregestational diabetes (AOR: 7.84, 95% CI: 4.24–14.37), chronic hypertension (AOR: 4.37, 95% CI: 2.01–9.49), pregnancy-induced hypertension (AOR: 2.65, 95% CI: 1.92–3.66) and gestational diabetes (AOR: 1.96, 95% CI: 1.57–2.44) compared to mothers delivering at 39 weeks. The elective caesarean section rate was highest at 37 weeks (783, 43.4%) compared to 38 weeks (737, 31.1%) or higher gestations. Delivery at 37 weeks was associated with inferior neonatal outcomes of 5-min APGAR <8 (AOR: 3.04, 95% CI: 1.36–6.76), requiring resuscitation (AOR: 1.74, 95% CI: 1.27–2.38) and admission to intensive care (AOR: 1.62, 95% CI: 1.09–2.41) compared to 38 weeks.</div></div><div><h3>Interpretation</h3><div>Neonates born at 38 weeks showed better outcomes than those born at 37 weeks. When elective delivery is necessary, postponing it from 37 weeks to at least 38 weeks would positively impact neonatal outcomes.</div></div><div><h3>Funding</h3><div><span>UNICEF</span>, Sri Lanka, funded the Sri Lanka Birth Weight Study. No funding obtained for this manuscript.</div></div>","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":"42 ","pages":"Article 100677"},"PeriodicalIF":6.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145222996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indicators of psychiatric institutionalization in Southeast Asia between 1990 and 2024 1990年至2024年间东南亚精神病院的指标

IF 6.2 Q1 HEALTH CARE SCIENCES & SERVICES

The Lancet regional health. Southeast Asia

Pub Date : 2025-11-01 DOI: 10.1016/j.lansea.2025.100690

Adrian P. Mundt , S.M. Yasir Arafat , Chencho Dorji , Avinash Desousa , Rakesh K. Chadda , Guru S. Gowda , Cristian Orus , Muralidharan Kesavan , Athifa Ibrahim , Nagendra P. Luitel , Harischandra Gambheera , Phunnapa Kittirattanapaiboon , Stefan Priebe , Enzo Rozas-Serri

Background

This study aimed to assess indicators of psychiatric institutionalization and their changes over time across the Southeast Asia Region (SEAR).

Methods

We collected numbers of psychiatric beds, specialized forensic psychiatric beds, beds in residential facilities for people living with chronic mental illness and prison populations in the 11 SEAR member states between 1990 and 2024 using primary and secondary data sources. We calculated median rates per 100,000 population, as well as percent changes of the median rates between the first and last available data points. We also compared findings in SEAR with OECD countries.

Findings

Psychiatric bed numbers and prison population were available from 10 countries. Bed prevalence increased in seven countries, but decreased in three. The median psychiatric bed prevalence was 1.5 at the first and 2.9 per 100,000 population at the last data point (+94%). The prison population increased in nine countries, with the median rate changing from 60 to 123 (+106%). Data on specialized forensic psychiatric beds were available from seven countries, with a range of 0.0–0.5 beds at the last data point. Based on data from five countries, the median prevalence of beds in residential facilities increased from 1.3 to 2.3. Psychiatric bed prevalence was on average about 5% of that in the OECD, while prison population rates were similar to those in OECD countries.

Interpretation

Psychiatric bed provision in the SEAR is among the lowest worldwide. In contrast, incarceration rates are similar to those in high-income regions. Most countries have increased the prevalence of psychiatric beds over the past three decades, but they remain scarce, and further investments need consideration.

Funding

Agencia Nacional de Investigación y Desarrollo (ANID), Chile.

本研究旨在评估东南亚地区（SEAR）精神病院的指标及其随时间的变化。方法采用第一手和二手数据来源，收集1990年至2024年间11个SEAR成员国的精神病学床位、专业法医精神病学床位、慢性精神疾病患者居住设施床位和监狱人口数量。我们计算了每10万人的中位数率，以及第一个和最后一个可用数据点之间中位数率的百分比变化。我们还将SEAR的研究结果与经合组织国家进行了比较。调查结果：有10个国家的精神病病床数量和监狱人口。7个国家的床上流行率上升，但有3个国家下降。在最后一个数据点，精神病床位患病率中位数为每10万人中有2.9人（+94%）。9个国家的监狱人口增加，中位数从60人增加到123人（+106%）。有7个国家提供了关于专门法医精神病病床的数据，在最后一个数据点，病床的范围为0.0-0.5张。根据来自五个国家的数据，住宅设施中床位的中位数患病率从1.3增加到2.3。精神科病床患病率平均约为经合组织国家的5%，而监狱人口比率与经合组织国家相似。解释东南亚地区的精神病床位供应是世界上最低的。相比之下，监禁率与高收入地区相似。在过去的三十年里，大多数国家都增加了精神病病床的使用率，但它们仍然稀缺，需要考虑进一步的投资。智利国家资助机构Investigación与发展基金（ANID）。

{"title":"Indicators of psychiatric institutionalization in Southeast Asia between 1990 and 2024","authors":"Adrian P. Mundt , S.M. Yasir Arafat , Chencho Dorji , Avinash Desousa , Rakesh K. Chadda , Guru S. Gowda , Cristian Orus , Muralidharan Kesavan , Athifa Ibrahim , Nagendra P. Luitel , Harischandra Gambheera , Phunnapa Kittirattanapaiboon , Stefan Priebe , Enzo Rozas-Serri","doi":"10.1016/j.lansea.2025.100690","DOIUrl":"10.1016/j.lansea.2025.100690","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to assess indicators of psychiatric institutionalization and their changes over time across the Southeast Asia Region (SEAR).</div></div><div><h3>Methods</h3><div>We collected numbers of psychiatric beds, specialized forensic psychiatric beds, beds in residential facilities for people living with chronic mental illness and prison populations in the 11 SEAR member states between 1990 and 2024 using primary and secondary data sources. We calculated median rates per 100,000 population, as well as percent changes of the median rates between the first and last available data points. We also compared findings in SEAR with OECD countries.</div></div><div><h3>Findings</h3><div>Psychiatric bed numbers and prison population were available from 10 countries. Bed prevalence increased in seven countries, but decreased in three. The median psychiatric bed prevalence was 1.5 at the first and 2.9 per 100,000 population at the last data point (+94%). The prison population increased in nine countries, with the median rate changing from 60 to 123 (+106%). Data on specialized forensic psychiatric beds were available from seven countries, with a range of 0.0–0.5 beds at the last data point. Based on data from five countries, the median prevalence of beds in residential facilities increased from 1.3 to 2.3. Psychiatric bed prevalence was on average about 5% of that in the OECD, while prison population rates were similar to those in OECD countries.</div></div><div><h3>Interpretation</h3><div>Psychiatric bed provision in the SEAR is among the lowest worldwide. In contrast, incarceration rates are similar to those in high-income regions. Most countries have increased the prevalence of psychiatric beds over the past three decades, but they remain scarce, and further investments need consideration.</div></div><div><h3>Funding</h3><div><span>Agencia Nacional de Investigación y Desarrollo</span> (ANID), Chile.</div></div>","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":"42 ","pages":"Article 100690"},"PeriodicalIF":6.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145418014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should pregabalin be regulated under the Narcotic Drugs and Psychotropic Substances (NDPS) Act of India? 普瑞巴林是否应受印度麻醉药品和精神药物（NDPS）法案的监管？

IF 6.2 Q1 HEALTH CARE SCIENCES & SERVICES

The Lancet regional health. Southeast Asia

Pub Date : 2025-11-01 Epub Date: 2025-10-29 DOI: 10.1016/j.lansea.2025.100687

Surender Grover, Jadeer K. Muhammed, Atul Ambekar, Priyanka Saha

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

The Lancet regional health. Southeast Asia

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀